Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Gene Mutation Linked to Inherited Risk of Common Form of Childhood Leukemia

Published: Wednesday, September 11, 2013
Last Updated: Wednesday, September 11, 2013
Bookmark and Share
A new international study has discovered a gene mutation linked with a rare inherited form of childhood acute lymphoblastic leukemia (ALL).

“This is the first genetic susceptibility specific to childhood ALL that has ever been seen, so this is a new syndrome,” says Kenneth Offit, Chief of the Clinical Genetics Service and lead investigator of the study, which was published online by the journal Nature Genetics on September 8. “When you look at this story, there’s also the human context of a family with small children who have more than their share of medical challenges.”

The gene, known as PAX5, works as a transcription factor or “master gene” by regulating the activity of numerous other genes and is essential for maintaining the identity and function of mature immune cells called B cells, which are integral to the development of ALL.

Dr. Offit’s work focuses on defining genetic factors that cause an increased susceptibility to cancer. In 1996, the same gene-sequencing approach used in the new research helped his team identify BRCA2, the most common mutation associated with an increased risk of breast and ovarian cancer among individuals of Ashkenazi Jewish ancestry.

 “Like Lightning Striking Multiple Times”

About five years ago, Memorial Sloan-Kettering physicians became aware that a family being cared for by their team had multiple members from several generations diagnosed with ALL in childhood. Despite ALL’s high cure rate — due in large part to several successful treatment protocols developed at Memorial Sloan-Kettering — the family had lost one child to the disease.

Family members were strongly committed to helping with this research, Dr. Offit recalls. Seeing so many cases of the same cancer in the same family “was like lightning striking multiple times — there’s a sense of bewilderment when this calamity repeats itself.”

By analyzing their DNA through genome sequencing, and comparing thousands of genes from people with and without ALL, the researchers discovered that all members of the family who had the disease and were involved in the study carried the PAX5 mutation.

Scientists from St. Jude Children’s Research Hospital, the University of Washington, and the Broad Institute of Harvard and MIT were the lead collaborators on the study, and were joined by other institutions around the globe. The researchers also identified a second leukemia-prone family unrelated to the family treated at Memorial Sloan-Kettering.

“In this second family, it was the same exact gene mutation,” Dr. Offit says. “The chances of that happening are incredibly small. It’s like a single misspelling in the entire encyclopedia.”

In addition, the researchers carried out a series of experiments that confirmed that the gene mutation caused significant changes in the gene’s function.

Additional Contributing Factors under Investigation

Beyond the mutated PAX5 gene, other factors led affected children to develop ALL. In all family members who developed ALL, one of the two copies of the PAX5 gene was missing, leaving only the mutated version. Some family members who didn’t develop ALL — such as a parent of a child who had the disease — carried the mutation without becoming ill, however.

The researchers believe additional factors — which are currently under examination but as yet unknown — played a role in the development of ALL in these children.

“It’s clear we need additional genetic events to happen for this disease to take over,” says Cornelius Miething, a research associate working with biologist Scott W. Lowe, chair of Memorial Sloan-Kettering’s Geoffrey Beene Cancer Research Center, and a senior coauthor of the study.

Preventing Future ALL in Affected Families

Dr. Offit hopes that ongoing research will determine what percentage of childhood ALL patients have the PAX5 mutation. Current estimates suggest that the gene mutation is quite rare, and Memorial Sloan-Kettering will again team with the St. Jude group led by physician-scientist Charles Mullighan to address the question.

But even before such information is ascertained, an immediate application of the research is the prevention of ALL in families in which leukemia is already prevalent. Concerned prospective parents can seek in vitro fertilization that includes preimplantation genetic diagnosis, also known as PGD, a technique that can identify embryos with genetic defects before pregnancy is attempted.

“It could provide a way to preemptively allow parents to check for the mutation so they can make better-informed reproductive decisions,” says medical geneticist Kasmintan Schrader, who is a postdoctoral researcher in Dr. Offit’s lab.

Additionally, the newly discovered gene mutation may someday help scientists determine how to target transcription factors to treat other, more common forms of leukemia, Dr. Offit says, since the PAX5 mutation is also present in some non-inherited leukemias.

“Our focus is understanding why the cancers occur,” Dr. Offit says. “With better understanding, we’re better able to target prevention as well as therapy. We want to test this idea that there may be more typical forms of leukemia that do not appear to be hereditary but may in fact have these same genetic alterations occurring spontaneously and lead to cancer forming in the first place. That research is in progress now, and if this model proves correct, these findings will have much broader relevance to childhood leukemia and possibly other cancers.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Memorial Sloan Kettering Cancer Center, Quest Diagnostics Partner
Collaboration will offer diagnostic insights into gene mutations in solid tumor cancers, aiding therapy selection and prognosis for patients and advance research.
Monday, June 02, 2014
MSK to Launch New Cancer Center with $100M Gift
New Marie-Josée and Henry R. Kravis Center for Molecular Oncology aims to analyze 10,000 patient tumors in its first year.
Wednesday, May 21, 2014
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Cancer Related Immune Response Genes Uncovered
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer.
Deciphering Inactive X Chromosomes
Untangling the Barr body of inactive X chromosomes valuable for understanding chromosome structure and gene expression.
Micro Disease-Detecting Sensor Created
Researchers at McMaster University have created a microscopic disease-detecting sensor that can turn on to detect trace amounts of substances.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Uncovering a New Principle in Chemotherapy Resistance in Breast Cancer
The NIH study has revealed an entirely unexpected process for acquiring drug resistance that bypasses the need to re-establish DNA damage repair in breast cancers that have mutant BRCA1 or BRCA2 genes.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!